The APAC biopharmaceutical contract manufacturing market is at USD 1.38 billion in 2022 and is projected to grow at 2.16 billion in 2027 at a CAGR of 9.38%. Asia-Pacific is the fastest growing region due to low labour costs, regulatory relaxation, abundance availability of raw materials, infrastructure facility, rise in generic demands, increased production capabilities, the presence of a large number of domestic and international players and comparatively low investments required for the establishment of manufacturing facilities, as opposed to western countries. This new trend of outsourcing is resulting in many benefits to the CMOs in multiple Asian countries, such as Singapore, South Korea, India, and China. Many companies see growth opportunities in this sector.

The 2nd Biologics Contract Manufacturing Asia 2023 is a premium event that focuses exclusively on Contract Manufacturing in Asia-Pacific. The conference addresses the growing market of contract manufacturing, the predicted trends in the market, challenges faced by CMOs/ CDMOs, as well as the solutions and opportunities moving forward. We bring the entire eco-system together – from experts in the biologics manufacturing space, to academia and regulatory – to foster partnerships, share insights and stay on the cutting edge of new developments.